 Connection
Brian Freed to Graft Rejection
This is a "connection" page, showing publications Brian Freed has written about Graft Rejection.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.557 |
|
|
|
-
Davis S, Gralla J, Klem P, Tong S, Wedermyer G, Freed B, Wiseman A, Cooper JE. Lower tacrolimus exposure and time in therapeutic range increase the risk of de novo donor-specific antibodies in the first year of kidney transplantation. Am J Transplant. 2018 04; 18(4):907-915.
Score: 0.108
-
Adebiyi OO, Gralla J, Klem P, Freed B, Davis S, Wiseman AC, Cooper JE. Clinical Significance of Pretransplant Donor-Specific Antibodies in the Setting of Negative Cell-Based Flow Cytometry Crossmatching in Kidney Transplant Recipients. Am J Transplant. 2016 12; 16(12):3458-3467.
Score: 0.098
-
Freed BM, Bennett JA, Rosano TG, Brooks CA, Cramer SM, Lempert N. Assessment of the in vivo immunosuppressive activity of the major cyclosporine metabolite by leukemia allograft rejection. Transplantation. 1992 Feb; 53(2):456-60.
Score: 0.072
-
Lempert N, Laffin RJ, Fitzgerald K, Freed BM. Elevation of serum C-reactive protein levels during graft rejection. Transplant Proc. 1987 Feb; 19(1 Pt 2):1683-5.
Score: 0.051
-
Gibney EM, Cagle LR, Freed B, Warnell SE, Chan L, Wiseman AC. Detection of donor-specific antibodies using HLA-coated microspheres: another tool for kidney transplant risk stratification. Nephrol Dial Transplant. 2006 Sep; 21(9):2625-9.
Score: 0.048
-
Freed B, Walsh A, Pietrocola D, MacDowell R, Laffin R, Lempert N. Early detection of renal allograft rejection by serial monitoring of serum C-reactive protein. Transplantation. 1984 Feb; 37(2):215-18.
Score: 0.042
-
Supon P, Constantino D, Hao P, Cagle L, Hahn A, Conti DJ, Freed BM. Prevalence of donor-specific anti-HLA antibodies during episodes of renal allograft rejection. Transplantation. 2001 Feb 27; 71(4):577-80.
Score: 0.034
-
Stites E, Renner B, Laskowski J, Le Quintrec M, You Z, Freed B, Cooper J, Jalal D, Thurman JM. Complement fragments are biomarkers of antibody-mediated endothelial injury. Mol Immunol. 2020 02; 118:142-152.
Score: 0.031
-
Isenberg A, Singh TP, Shen GK, Freed BM, Conti DJ. Selective CellCept therapy in high-risk renal transplant recipients. Transplant Proc. 1998 Jun; 30(4):1188-9.
Score: 0.028
-
Conti DJ, Shen G, Singh T, Isenberg A, Freed BM. Ganciclovir prophylaxis of cytomegalovirus disease. Transplant Proc. 1997 Feb-Mar; 29(1-2):804-6.
Score: 0.026
-
Singh TP, Gruber SA, Lempert N, Freed B, Conti DJ. Efficacy of cytomegalovirus prophylaxis in renal retransplantation. Transplant Proc. 1995 Feb; 27(1):964-5.
Score: 0.006
-
Conti DJ, Freed BM, Gruber SA, Lempert N. Prophylaxis of primary cytomegalovirus disease in renal transplant recipients. A trial of ganciclovir vs immunoglobulin. Arch Surg. 1994 Apr; 129(4):443-7.
Score: 0.005
-
Conti DJ, Freed BM, Lempert N. Prophylactic immunoglobulin therapy improves the outcome of renal transplantation in recipients at risk for primary cytomegalovirus disease. Transplant Proc. 1993 Feb; 25(1 Pt 2):1421-2.
Score: 0.005
-
Rosano TG, Pell MA, Freed BM, Dybas MT, Lempert N. Cyclosporine and metabolites in blood from renal allograft recipients with nephrotoxicity, rejection, or good renal function: comparative high-performance liquid chromatography and monoclonal radioimmunoassay studies. Transplant Proc. 1988 Apr; 20(2 Suppl 2):330-8.
Score: 0.003
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|